A-395 is a potent and selective inhibitor of EED/PRC2 interaction (SPR Kd=1.5 nM, 1:1 EED/A-395 binding; Ki=0.5 nM). Calculated physicochemical properties: MW=486.65, PSA=55.5, AlogP=3.37, clogD pH 7=1.74, HBDon=0, HBAcc=5, Nrot=5, Ligand Efficiency (LE)=0.371, Lipophilicity Ligand Efficiency (LipE)=7.655. A co-crystal structure is available (PDB code 5K0M, 1.83 Å).
It works well in cells and was reported to inhibit both H3K27me2 and H3K27me3 marks with IC50=390 nM, 90 nM, respectively, in human rhabdoid tumor cell line RD after 72 hours. A-395 inhibited proliferation in multiple myeloma cell lines with EC50s=1-2 uM after 10 days in RPMI 8226, MM.1s and L-363 cell lines. A-395 is highly selective and, thus, can be used to tease out the EED pharmacology in cells and its role in cancer and other diseases. It was selective against a panel of 32 diverse epigenetic methyltransferases including lysine, arginine, and DNA methyltransferases as well as against a survey of other epigenetic ‘reader domains’, including the WD-40-containing protein WDR5 (as measured by TSA) and against the chromodomain of PcG protein CBX7 (as measured by fluorescence polarization).
A-395 was tested in a xenograft model using the DLBCL Pfeiffer cells in SCID mice. A-395 was administered at a very high concentration (300 mg/kg subcutaneously, twice per week for 35 days) and showed significant reduction of the tumor volume up to 150 days as well as the H3K27m3 levels measured after 1 week compared with vehicle. Based on reported pharmacokinetic studies, subcutaneous delivery of A-395 at 300 mg/kg can maintain an unbound 90% effective concentration (EC90) for at least 48 hours. Based on the long lasting exposure after the subcutaneous administration, I suspect that A-395 may also be administered IV or IP with a proper formulation provided that the compound is soluble at the tested concentration. Development of an improved analog with good oral, IV or IP exposure would be beneficial. Selectivity profiling in a broad CEREP panel would help determine if any of the phenotypic or in vivo readout is partially due to some off-target activity. Also there is no evidence that the H3K27m3-mark reduction is responsible for the phenotypic and in vivo response.
16 Aug 2017 )